跳至主要内容
临床试验/NCT04679597
NCT04679597已完成不适用

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

Institute of Oncology Ljubljana0 个研究点目标入组 161 人开始时间: 2016年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
161
主要终点
pathological complete response

研究概览

简要总结

In a retrospective study, the investigators will compare patients with locally advanced rectal cancer with high risk factors for failure who were treated with standard therapy or with total neoadjuvant therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • histologically proven locally advanced rectal cancer and
  • the presence of one of the factors: T4, N2, positive mesorectal fascia, presence of extramural vascular invasion or presence of lateral lymph node.

排除标准

  • distant metastases,
  • concomitant malignancy,
  • inflammatory bowel disease, or
  • malabsorption syndrome.

研究组 & 干预措施

total neoadjuvant therapy

Total neoadjuvant therapy consisted of 12 weeks of induction chemotherapy with CAPOX or FOLFOX, chemoradiotherapy with capecitabine and six to eight weeks of consolidation chemotherapy with CAPOX or FOLFOX prior to surgery.

干预措施: Capecitabine (Drug)

standard therapy

Standard therapy (neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy)

干预措施: Capecitabine (Drug)

结局指标

主要结局

pathological complete response

时间窗: during surgery

pathological complete response is defined as the absence of tumor cells in the surgical resection

次要结局

  • Neoadjuvant rectal cancer score(during treatment, assessed up to 10 days)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Total Neoadjuvant Therapy Versus Standard Therapy of... | 临床试验